Novo CEO Mike Doustdar pushes semaglutide from weight loss into longevity and aesthetics

Novo Nordisk CEO Mike Doustdar used the American Diabetes Association conference in New Orleans to make a very pointed pivot: semaglutide might matter for longevity and even aesthetics, not only for weight loss. In an interview Sunday, Doustdar said the company is increasingly exploring whether semaglutide could slow conditions associated with aging, and he even answered “Yes” when asked if Novo would consider investing in skincare, hair loss, and other appearance-related conditions.

Why does this matter right now? Because Novo’s market position is under pressure. The company’s focus on just two core areas, obesity and diabetes, has “rankled some investors” who want diversification as generic competition looms and rivals such as Eli Lilly & Co. grab more share. Meanwhile, Novo’s shares have fallen more than 12.7% this year through Friday’s close amid pricing pressure and increasing competition. Doustdar’s comments are basically the company signaling that the next phase is about expanding what its drugs are “for,” which is a strategic lever when pure market share is getting harder to defend.

Doustdar anchored his longevity case in what Novo has already told regulators and the market: semaglutide’s benefits may show up before patients lose significant weight. He pointed to a “growing body of research” and to studies where Novo has said semaglutide protects vital organs including the heart, liver, and kidneys, with those benefits appearing to emerge before weight loss. His language was direct: if semaglutide “slows down a lot of those conditions as a molecule,” then Novo is “already in a bit of a longevity game.” That is a meaningful nuance for executives watching the GLP-1 space. It reframes the drug from a body-weight intervention into a potential disease-modifying, multi-system therapy.

Novo’s internal science messaging is starting to look more like a longevity platform pitch. At the same ADA conference, Novo researchers presented new data showing semaglutide reduced the “biological age of the heart and kidneys” as measured by experimental protein-based aging clocks. The analysis also associated those effects with lower mortality risk. Importantly, Doustdar and the research framing stop short of claiming proof that the drug slows the aging process itself, noting that the analysis does not prove semaglutide slows aging. For decision-makers, that distinction is crucial. It keeps Novo inside the lane of evidence-based claims while still building a narrative that could support longer-term trials, new endpoints, and expanded indications.

The CEO also described a shift in how Novo is directing its scientists: increasingly asking them to look beyond weight loss and identify what other diseases future generations of GLP-1 drugs could be designed to remedy. He suggested weight reduction could become “just an appendix of a different purpose.” In plain English, Novo is trying to treat obesity medicine as the entry point, not the destination. That is a clever strategic story because it matches how patients and clinicians actually experience GLP-1s today, but it also addresses an investor worry: if competitors copy dosing and indications, the winners might be the companies that can credibly expand the “reason to prescribe.”

This push also has a consumer and market-sensing angle. Doustdar said, “We have to be obsessed with what our patients want.” That matters because it’s not only about clinical outcomes. When he was asked at the ADA conference whether he’d consider investing in skincare, hair loss, and other appearance-related conditions that are increasingly intertwined with the rise of weight-loss drugs, he answered “Yes,” quickly. He didn’t point to a specific breakthrough. Instead, he framed the opportunity as an extension of Novo’s longstanding strategy: responding to market needs for improved patient outcomes.

Novo’s leadership has been signaling similar thinking for a while. At the company’s annual general meeting earlier this year in Copenhagen, Chairman Lars Rebien Sorensen told reporters that Novo was focused on understanding its consumers and finding out “what else they need.” He cited possible interest areas including knee pain, psoriasis, and inflammation, while stressing Novo wouldn’t necessarily enter all of those fields. In other words, the longevity and aesthetics comments are not a random side quest. They fit a broader board-level theme: expanding the definition of what “patients need” beyond the original diabetes and obesity core.

For competitors, the strategic implication is pretty blunt. Lilly’s portfolio spans oncology to immunology and neuroscience, while Novo gets more than 90% of its revenue from diabetes and obesity treatments. That concentration makes diversification feel less like ambition and more like risk management. Even some analysts who attended the meeting walked away sensing “change is afoot” after a difficult period. BMO Capital Markets analyst Evan Seigerman wrote in a Sunday note that with Doustdar at the helm, “we get the sense that change is a fundamental priority,” pushing Novo to reevaluate historical processes regardless of how established they are. The stakes for executives in the GLP-1 era are straightforward: if Novo can convert early organ-protection and aging-related signals into future disease areas, it may defend pricing power and relevance even as competition increases. If it cannot, investors may keep pressing for the diversification they worry Novo lacks.

The real question now is whether this longevity and aesthetics framing becomes a pipeline reality: new studies, new endpoints, and new regulatory paths. The source makes clear that semaglutide’s aging links are promising but not proven as “slowing the aging process itself.” Still, Novo is clearly trying to position semaglutide as something bigger than a weight-loss headline. For anyone tracking drug industry evolution, that is the move: take the molecule that already changed one clinical world, and try to claim it could help reshape several others.